Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. filed an amended current report to replace an earlier press release exhibit with the correct version. The updated release confirms that the board has begun exploring a range of strategic alternatives aimed at maximizing shareholder value, following a review of current market conditions.
The company states it expects this strategic review process to align with completion of clinical work supporting a planned New Drug Application for its crofelemer drug candidate for rare intestinal failure diseases. Jaguar emphasizes that these are forward-looking statements subject to significant risks and uncertainties.
Jaguar Health, Inc. has started a formal process to explore a range of strategic alternatives aimed at maximizing shareholder value. The Board’s decision follows an evaluation of current market conditions.
The company expects the timing of this review to align with completion of clinical work supporting a planned New Drug Application for its crofelemer prescription drug candidate targeting rare intestinal failure diseases. Jaguar emphasizes that these plans are forward-looking and subject to significant risks and uncertainties described in its prior SEC reports.
Jaguar Health, Inc. entered several financing-related agreements affecting its royalty obligations, debt maturity, and equity structure. The company amended two royalty interests with Uptown Capital and Streeterville Capital, each originally for $12 million, so that beginning on October 1, 2026 the monthly royalty payment will be the greater of $750,000 or the royalty amount otherwise due under Section 2.1 of each agreement. Streeterville’s royalty amendment also pushes the start of monthly payments from July 1, 2026 to October 1, 2026.
Jaguar and its subsidiary Napo Pharmaceuticals also amended a secured promissory note originally issued to Streeterville in the principal amount of $6,220,812.50, extending the note’s maturity date from July 1, 2026 to October 1, 2026. In separate, privately negotiated exchange agreements with Streeterville, Jaguar issued 34,798, 36,796 and 38,655 common shares in three tranches in exchange for an aggregate 3.8, 3.4 and 3.68 shares of Series Q Perpetual Preferred Stock, respectively. The preferred shares received in each exchange were cancelled and retired, and in the aggregate the related common stock issuance exceeded 5% of Jaguar’s common shares outstanding as last reported in its most recent Form 10-Q.
Jaguar Health arranged two linked financings to bolster access to capital and liquidity. The company entered a common stock equity line of credit with an institutional investor, who is committed to purchase up to $40 million of Jaguar’s common stock, subject to volume, dollar and 4.99% beneficial ownership limits.
Jaguar will issue $800,000 of commitment shares valued at the VWAP on the ELOC registration statement’s effective date, and will register both these and future ELOC shares on a Form S-1. Separately, the company completed a private placement of 240 shares of Series P preferred stock for $2 million, carrying an 8% annual dividend payable in cash or stock.
The preferred stock has no conversion rights but features complex mandatory, optional and forced redemption mechanics, often settled in common shares using price-based formulas, plus 4.99%–9.99% beneficial ownership caps and 19.99% issuance limits tied to stockholder approvals and Nasdaq rules.
Jaguar Health, Inc. reported the final voting results of its 2026 Annual Meeting of Stockholders, where all five proposals were approved. The meeting, originally held May 22 and adjourned twice, reconvened on June 8, 2026 with 7,169,152 shares represented out of 14,044,277 shares entitled to vote as of April 15, 2026.
Stockholders elected director nominee John Micek III and approved additional proposals, each receiving millions of votes in favor with broker non-votes reported where applicable. Jaguar also highlighted that founder, president and CEO Lisa Conte is scheduled to present virtually at the Emerging Growth Conference on June 10, 2026.
Jaguar Health, Inc. entered two privately negotiated exchange agreements with Streeterville Capital to swap Series Q Perpetual Preferred Stock for common shares and further adjourned its 2026 Annual Meeting of Stockholders.
On May 26, 2026 the company issued 31,958 common shares in exchange for 3.72 Series Q preferred shares, which were then cancelled. On June 1, 2026 it issued 32,710 common shares in exchange for 4.2 additional Series Q preferred shares, which were also cancelled. These exchanges were completed under Section 3(a)(9) of the Securities Act.
The 2026 Annual Meeting, previously adjourned, was further adjourned to June 8, 2026 at 8:30 a.m. Pacific Time at Jaguar Health’s San Francisco offices, with the record date remaining April 15, 2026. Stockholders who have already voted and do not wish to change their vote do not need to take any action.
Jaguar Health, Inc. has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company on May 26, 2026, and its shares continue to trade on Nasdaq, although a Nasdaq Hearings Panel will retain jurisdiction over the listing until September 1, 2026.
The company is now subject to a one-year Mandatory Panel Monitor period through May 26, 2027. If during this time the closing bid falls below $1.00 per share for 30 consecutive business days, Nasdaq would issue a delist determination without granting the usual 180‑day grace period, though Jaguar could request a new hearing.
In the accompanying press release, Jaguar highlighted that net revenue in Q1 2026 increased 816% versus Q1 2025 and 527% versus Q4 2025, driven by a U.S. out‑license agreement for Mytesi and Canalevia‑CA1 with Future Pak. The company also reiterated its focus on a pivotal‑stage development program for crofelemer in rare intestinal failure indications, targeting a new drug application around mid‑2027 and seeking a development and commercialization partner.
Jaguar Health, Inc. entered into two privately negotiated exchange agreements with Streeterville Capital, LLC, issuing 54,222 shares of common stock in exchange for 7.96 shares of Series Q Perpetual Preferred Stock, which were cancelled and retired. This follows an earlier sale of 408 Series Q preferred shares to Streeterville in prior exchange transactions.
The company also convened its 2026 Annual Meeting of Stockholders and then adjourned it to June 2, 2026 after discussions with Nasdaq, so it can provide additional information on certain proxy proposals via a forthcoming supplement. The record date for the meeting remains April 15, 2026.
Jaguar Health reported a sharp turnaround in its first quarter 2026 results, largely due to a major license deal for U.S. commercial rights to Mytesi and Canalevia-CA1. Total net revenue rose to $20,272 thousand in Q1 2026 from $2,214 thousand in Q1 2025, an 816% increase, as license and grant revenue jumped to $19,068 thousand.
Product revenue declined to $1,204 thousand from $2,171 thousand, down 45%. Income from operations moved to a profit of $10,182 thousand compared with a loss of $9,421 thousand, while net loss attributable to common stockholders narrowed to $7,015 thousand from $10,464 thousand. Non-GAAP EBITDA improved to a loss of $5,688 thousand from a loss of $9,739 thousand, and non-GAAP Recurring EBITDA improved to a loss of $5,060 thousand.
The company highlighted ongoing development of crofelemer for rare intestinal failure disorders and announced upcoming crofelemer presentations at the ESPGHAN meeting in June 2026. Jaguar also plans an investor webcast on May 26, 2026, and a management presentation at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
Jaguar Health reported a sharp turnaround in its first quarter 2026 results, largely due to a major license deal for U.S. commercial rights to Mytesi and Canalevia-CA1. Total net revenue rose to $20,272 thousand in Q1 2026 from $2,214 thousand in Q1 2025, an 816% increase, as license and grant revenue jumped to $19,068 thousand.
Product revenue declined to $1,204 thousand from $2,171 thousand, down 45%. Income from operations moved to a profit of $10,182 thousand compared with a loss of $9,421 thousand, while net loss attributable to common stockholders narrowed to $7,015 thousand from $10,464 thousand. Non-GAAP EBITDA improved to a loss of $5,688 thousand from a loss of $9,739 thousand, and non-GAAP Recurring EBITDA improved to a loss of $5,060 thousand.
The company highlighted ongoing development of crofelemer for rare intestinal failure disorders and announced upcoming crofelemer presentations at the ESPGHAN meeting in June 2026. Jaguar also plans an investor webcast on May 26, 2026, and a management presentation at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
Jaguar Health reported a sharp turnaround for the quarter ended March 31, 2026, driven by a major licensing transaction. Total revenue rose to $20.3 million from $2.2 million a year earlier, mainly from $19.0 million of license revenue under a new Mytesi and Canalevia license and supply agreement with Woodward, while product revenue declined.
The company posted net income of $8.7 million versus a $10.6 million loss in 2025, but common shareholders still saw a net loss of $7.0 million after $9.5 million of Series O preferred stock dividends and over $6.0 million of deemed preferred dividends. Cash was $7.3 million with $2.8 million in restricted cash, against total notes payable of about $33.2 million and a stockholders’ deficit of $15.8 million. Management disclosed recurring losses, a $391.1 million accumulated deficit and stated that these conditions raise substantial doubt about Jaguar’s ability to continue as a going concern over the next 12 months, even after receiving a $16.0 million upfront payment from a separate license and supply agreement.
Jaguar Health reported a sharp turnaround for the quarter ended March 31, 2026, driven by a major licensing transaction. Total revenue rose to $20.3 million from $2.2 million a year earlier, mainly from $19.0 million of license revenue under a new Mytesi and Canalevia license and supply agreement with Woodward, while product revenue declined.
The company posted net income of $8.7 million versus a $10.6 million loss in 2025, but common shareholders still saw a net loss of $7.0 million after $9.5 million of Series O preferred stock dividends and over $6.0 million of deemed preferred dividends. Cash was $7.3 million with $2.8 million in restricted cash, against total notes payable of about $33.2 million and a stockholders’ deficit of $15.8 million. Management disclosed recurring losses, a $391.1 million accumulated deficit and stated that these conditions raise substantial doubt about Jaguar’s ability to continue as a going concern over the next 12 months, even after receiving a $16.0 million upfront payment from a separate license and supply agreement.